The leaves of the ginkgo biloba tree possess fibrinolytic properties (the ability to dissolve blood clots). These clot-busting compounds include diterpene terpenoids, notably ginkgolides and bilobalide. Due to its fibrinolytic properties, ginkgo supplements are often used to improve blood flow to the brain, increase memory retention, and improve cognitive function. Today, this compound could be used to combat the influx of cardiovascular issues caused by lab engineered spike proteins.
The SARS-CoV-2 spike protein has been linked to the formation of micro clots and subsequent fibrosis, especially in vaccinated individuals whose immune systems cannot clear the spike protein. Cardiovascular patients who suffer from “long covid” often deal with blood clots and inflammation of the endothelial cells. Ginkgo can improve these conditions by dealing with inflammation of the inner lining of the blood vessels and by activating plasminogen.
Beyond its direct impact on clotting mechanisms, Ginkgo biloba has shown promise in alleviating the neurological symptoms associated with vaccine injuries and long COVID. Its neuroprotective properties, including anti-inflammatory and anti-apoptotic effects, suggest broader therapeutic potential in managing the multi-systemic impacts of the disease.
Human knowledge is under attack! Governments and powerful corporations are using censorship to wipe out humanity's knowledge base about nutrition, herbs, self-reliance, natural immunity, food production, preparedness and much more. We are preserving human knowledge using AI technology while building the infrastructure of human freedom. Speak freely without censorship at the new decentralized, blockchain-power Brighteon.io. Explore our free, downloadable generative AI tools at Brighteon.AI. Support our efforts to build the infrastructure of human freedom by shopping at HealthRangerStore.com, featuring lab-tested, certified organic, non-GMO foods and nutritional solutions.
Moreover, research indicates that Ginkgo biloba may interfere with viral replication and inhibit inflammatory pathways associated with severe COVID-19 outcomes. In an enzymatic inhibition assay, researchers found that ginkgolide A can act as an irreversible inhibitor against SARS-CoV-2 papain-like protease. This dual-action approach — addressing both viral replication and vascular inflammation of the disease — positions Ginkgo biloba as a compelling candidate for integrative strategies for the management of vaccine injuries.
Ginkgo also contains flavonoids like quercetin, kaempferol, and isorhamnetin, which protect the cells from further spike protein damage, oxidation, and inflammation. In one study, kaempferol improves the recovery of cardiac function, reduces intracellular oxidation status and Myocardial Ischemia and inhibits myocardial apoptosis.
In another study, ginkgo biloba extract (GBE) influences the renin-angiotensin system and modulates inflammatory responses in cardiac cells via the TLR4/NF-?B pathway.
Most importantly, ginkgo biloba is a plasminogen activator. This process activates the body’s ability to break down clots. Ginkgo enhances endothelial cell function by stimulating the secretion of thrombomodulin and tissue-type plasminogen activator (t-PA), which are pivotal in clot breakdown and regulation of the coagulation cascade. These mechanisms not only support its role as a natural antithrombotic agent but also highlight its potential in preventing and treating conditions exacerbated by clotting disorders, such as those induced by the vaccine.
Due to these actions, ginkgo helps address other conditions, including:
Sources include: